Table: Incidence rates of NTM isolated from the respiratory tract of ICU patients.

| NTM                  | Outbreak cases/10,000 patient-days | Intervention cases/10,000 patient-days | IRR (95% CI) | P-value |
|----------------------|------------------------------------|----------------------------------------|--------------|---------|
| M. abscessus         | 16.6                               | 2.3                                    | 0.14         | (0.07–0.27) | <.0001  |
| M. chelonae/immunogenum | 12.0                             | 1.7                                    | 0.14         | (0.06–0.30) | <.0001  |
| M. avium complex     | 7.4                                | 3.8                                    | 0.48         | (0.24–0.94) | .03     |
| M. gordonae          | 4.6                                | 0.8                                    | 0.18         | (0.06–0.57) | .001    |
| Other NTM            | 0.5                                | 1.7                                    | 3.58         | (0.45–28.62) | .20     |
| All NTM (Total)      | 41.0                               | 9.9                                    | 0.24         | (0.17–0.34) | <.0001  |

Disclosures. All authors: No reported disclosures.

928. Major Decrease in Prevalence of Hepatitis C Viremia in Key Populations following the Second Year of Treatment as Prevention for Hepatitis C (TraP HepC) Program in Iceland

Magnús Göttsfredsson, MD, PhD1; Thorarinn Tyringsson, MD2; Valgurður Runarsdóttir, MD2; Ingunn Hansdottir, PhD2; Ottar M. Bergmann, MD2; Einars S. Björnsson, MD, PhD2; Birgir Johannsson, MD1; Bryndís Sigurðardóttir, MD2; Ragnarður H. Frödríksdóttir, RN, MBA1; Arthur Löve, MD, PhD2; Björn Ólafur J. Löve, MD, PhD2; Guðrun Sigurðsdóttir, MD, PhD2; Úlfabóð Hernandez, MSc2; María Heimisdóttir, MD, PhD, MBA1 and Sigurður Olafsson, MD1; 1Infectious Diseases, Landspítali University Hospital, Reykjavík, Iceland, 2Vogur Hospital, Reykjavík, Iceland, 3Gastroenterology and Hepatology, Landspítali University Hospital, Reykjavík, Iceland, 4Virology, Landspítali University Hospital, Reykjavík, Iceland, 5Science, Landspítali University Hospital, Reykjavík, Iceland, 6State Epidemiologist, Directorate of Health, Reykjavík, Iceland and 7Finance, Landspítali University Hospital, Reykjavík, Iceland

Session: 114. Hepatitis C: Epidemiology and Elimination
Friday, October 5, 2018: 8:45 AM

Background. Hepatitis C Virus (HCV) commonly affects people who inject drugs (PWID) and/or with history of injection drug use (IDU). They are also disproportionately represented in addiction treatment centers and the penitentiary system. In order to curtail spread of HCV it is therefore important to approach these groups. PWID and prisoners have been prioritized in the TraP HepC program. The impact can thus be assessed by monitoring HCV prevalence at sentinel sites, such as addiction hospitals and prisons.

Methods. TraP HepC offers direct-acting antiviral agents (DAAs) to all HCV patients in Iceland, starting in January 2016. HCV PCR is performed at the end of treatment and 12 weeks later (SVR12). PWID and prisoners are monitored for reinfection and retreated if needed. We compared the prevalence of HCV viremia among PWID admitted for treatment at Vogur addiction hospital and inmates of the penitentiary system, before and after 2 years of TraP HepC.

Results. Two years into the program 667 patients had been evaluated of which 632 were on their first course of DAAs and 7 were pending, representing 80% of the estimated total patient population. Of those who completed first treatment according to guidelines the SVR12 is 95.5%. Drop-out from first treatment was 8.2%; nevertheless, the SVR12 was >90% and most of the remaining viremic patients completed or are undergoing retreatment. In 2012–2015, prior to TraP HepC the prevalence of HCV viremia among actively injecting PWID admitted for addiction treatment was 47.9%, dropping to 39.8% in 2016 and 16.2% in 2017 (P<0.001). Likewise, the prevalence of viremia among patients with history of IDU but not recently injecting fell from 27.4% (2012–2015) to 19.8% in 2016 and 4.1% in 2017 (P<0.001). The prevalence of viremia among inmates of the penitentiary system was 29% prior to initiation of TraP HepC, dropping to 7% in 2017 (P<0.01). These results are not explained by declining IDU in the community.

Conclusion. On a population level the domestic transmission of HCV can be reduced by DAAs when combined with other efforts. Two years into the TraP HepC program the prevalence of viremia among two of the most important drivers of the epidemic has been markedly reduced. The program is ongoing, with further emphasis on increased intensity of screening, retreatment and harm reduction.

Disclosures. All authors: No reported disclosures.

930. HCV Treatment Is Associated With a Reduced Risk of Cardiovascular Disease Events: Results From ERCHIVES

Adeel Ajwad Butt, Professor of Medicine/Professor of Healthcare Policy and Research1; Peng Yan, MS; Ashfaq Shuaib, MD2; Abdul-Badi Abou-Samra, MD, PhD2; Obaid Saikd, MD3 and Matthew Freihberg, MD, MSc2; 1Medicine, Weill Cornell Medical College, New York, New York, 2VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 3University of Alberta, Alberta, Alberta, Canada, 4Hamad Medical Corporation, Doha, Qatar, 5Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee

Session: 114. Hepatitis C: Epidemiology and Elimination
Friday, October 5, 2018: 8:45 AM

Background. Studies reporting on the association between HCV and cardiovascular disease (CVD), and effect of HCV treatment upon future risk of CVD have shown mixed results.

Methods. Within ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans), we identified all persons treated for ≥7 weeks and propensity-score-matched group who never received HCV treatment. We excluded those with HIV, HBV, or previously diagnosed CVD. Incidence rate (per 1,000 person-years) and risk factors for CVD events (Cox proportional hazards analysis) were determined for various treatment groups. CVD events were identified using ICD-9CM/ICD-10 codes. Kaplan–Meier plots were generated to show and compare CVD-free survival by treatment status and attainment of SVR.

This abstract has been withdrawn at the author’s request.
Results. Among 32,575 treated and same number of untreated persons in the final dataset, median age was 58 years, 27% were Black race, and 96% were male. The incidence rate for CVD events/1,000 person-years (95% CI) among the treated was 19.10 (17.79, 20.50) vs. 32.37 (30.51, 34.33) among the untreated (P < 0.001). Treatment with a DAA regimen (vs. PEG/RBV; HR [95% CI] 0.68 [0.53, 0.88]) and achieving SVR (HR [95% CI] 0.76 [0.63, 0.92]) were associated with a lower risk of incidence CVD event (table). Kaplan-Meier curves demonstrated that untreated persons had a shorter CVD event-free survival during 30 months of follow-up compared with the treated persons. (figure; log-rank P < 0.0001)

Conclusion. HCV treatment is associated with a reduction in incident CVD events. Directly acting antiviral regimens (vs. PEG/RBV) and attainment of SVR (vs. PEG/RBV; HR [95% CI] 0.68 [0.53, 0.88]) and achieving SVR (HR [95% CI] 0.76 [0.63, 0.92]) were associated with a lower risk of incidence CVD event (table). Kaplan–Meier

Table 1: Factors associated with a diagnosis of incident cardiovascular disease event (multivariable Cox regression analysis) among those who were treated.

| Hazard ratio | 95% CI |
|--------------|--------|
| Age per 10 year increase | 1.72 (1.50, 1.99) |
| Race | |
| White (comparator) | 1 |
| Black | 1.21 (1.01, 1.46) |
| Hispanic | 0.74 (0.48, 1.13) |
| Others/unknown | 1.01 (0.79, 1.29) |
| Male sex (vs. female) | 1.04 (0.86, 1.28) |
| Smoking | |
| Never (comparator) | 1 |
| Former | 0.87 (0.68, 1.11) |
| Current | 1.34 (1.08, 1.66) |
| Body mass index, > 30 kg/m² (vs. ≤30) | 1.36 (1.17, 1.62) |
| Dyslipidemia | |
| | |
| Borderline or High | 0.79 (0.65, 0.96) |
| Liver fibrosis | |
| FIB-4 < 1.25 (comparator) | 1 |
| FIB-4 1.25 – 3.25 | 0.80 (0.69, 0.99) |
| FIB-4 > 3.25 | 0.62 (0.80, 1.29) |
| Chronic kidney disease (CKD) stage | |
| eGFR > 90 (comparator) | 1 |
| CKD stage 2 | 1.20 (1.02, 1.43) |
| CKD stage 3 | 1.93 (1.36, 2.75) |
| CKD stage 4-5 | 5.54 (2.59, 11.85) |
| HCV RNA, log₁₀ increase | |
| Treatment with a DAA regimen (vs. PEG+RBV) | 0.68 (0.53, 0.88) |
| SVR (vs. no SVR) | 0.76 (0.63, 0.92) |

Disclosures. A. Ajwad Butt, Gilead: Grant Investigator, Research grant.